* Journey Medical Corp DERM.OQ reported a quarterly
adjusted
loss of 53 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -57 cents. The mean expectation of
three analysts for the quarter was for a loss of 23 cents per
share. Wall Street expected results to range from -26 cents
to -21 cents per share.
* Revenue rose 6.7% to $13.03 million from a year ago;
analysts
expected $14.10 million.
* Journey Medical Corp's reported EPS for the quarter was a
loss
of 53 cents.
* The company reported a quarterly loss of $10.44 million.
* Journey Medical Corp shares had fallen by 4.6% this
quarter and
lost 39.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 23.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Journey Medical
Corp is $8.00
This summary was machine generated from LSEG data May 13 at
09:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.23 -0.53 Missed
Dec. 31 2023 -0.08 -0.12 Missed
Sep. 30 2023 -0.15 0.80 Beat
Jun. 30 2023 -0.33 -0.29 Beat